IGC — IGC Pharma, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1326205 ·
Last close
$0.19
Market Cap
$19.43M
52W High
$0.36
52W Low
$0.08
ADV30
481,992
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 328,000 | 61,000 | -1,931,000 | -2,046,000 | 9,729,000 | 377,000 | 3,228,000 |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 317,000 | 55,000 | -2,458,000 | -2,402,000 | 9,185,000 | 207,000 | 3,064,000 |
| Dec 2025 | 350,000 | 44,000 | -2,941,000 | -726,000 | 9,712,000 | 900,000 | 2,289,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,943,000
Investing CF
$-192,000
Financing CF
$5,935,000
CapEx
$-823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.09
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-127,292,000
Inventory
$638,000
Receivables
$101,000
ST Investments
$28,000
EBIT TTM
$-10,203,000
Pretax Income TTM
$-6,548,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,106,000
EBITDA
$-7,524,000
Free Cash Flow
$-2,521,375
Enterprise Value
$21,404,802
Total Cash
$354,000
Total Debt
$1,082,000
Shares Out
103,384,008
Trailing EPS
$-0.07
Book Value
$0.06
ROE
-83.3%
ROA
-50.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 1,271,000 | -7,446,000 | -7,121,000 | 8,747,000 | 2,417,000 | 6,330,000 | -4,065,000 |
| Mar 2024 | 1,345,000 | -9,798,000 | -13,000,000 | 9,902,000 | 2,581,000 | 7,321,000 | -5,199,000 |
| Mar 2023 | 911,000 | -11,571,000 | -11,506,000 | 17,178,000 | 2,267,000 | 14,911,000 | -7,047,000 |
| Mar 2022 | 397,000 | -15,428,000 | -15,016,000 | 26,834,000 | 2,942,000 | 23,892,000 | -7,462,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$9,496,000
Forward EPS
$-0.08
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COCP | Cocrystal Pharma, Inc. | $19.46M | $1.01 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $18.96M | $1.90 | — |
| EDSA | Edesa Biotech, Inc. | $18.90M | $1.96 | — |
| CELU | Celularity Inc | $18.53M | $0.57 | — |
| CUE | Cue Biopharma, Inc. | $20.56M | $2.83 | — |
News headlines (Yahoo Finance, 1h cache)
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
2026-11-18 13:00 · Yahoo
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 13:00 · Yahoo
IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
2026-11-05 15:18 · Yahoo
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
2026-10-13 12:00 · Yahoo
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
2026-09-28 12:00 · Yahoo
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
2026-08-11 12:30 · Yahoo
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
2026-07-29 12:30 · Yahoo
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
2026-07-09 13:00 · Yahoo
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
2026-04-22 12:30 · Yahoo
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
2026-06-02 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.